Adoptive Cell Therapy Across Cancer Diagnoses

NCT03296137 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

25

Enrollment

OTHER

Sponsor class

Conditions

Cancer

Interventions

BIOLOGICAL: Autologous tumor-infiltrating lymphocytes
DRUG: Ipilimumab
DRUG: Nivolumab
DRUG: proleukin
DRUG: Cyclophosphamide
DRUG: Fludara

Sponsor

Inge Marie Svane